Archives of oto-rhino-laryngology

, Volume 239, Issue 1, pp 15–23 | Cite as

The capsid antigen of Epstein-Barr virus in nasopharyngeal carcinomas: Comparison of serum antibody titre, cellular antigen content and histopathology

  • N. Falser


In a retrospective study of 21 patients with nasopharyngeal malignancies (lymphoepithelial carcinomas, both undifferentiated and dedifferentiated serological and immunohistological methods were used to examine the significance of the IgG- and IgM-antibody against the capsid antigen of Epstein-Barr virus for early detection and follow-up, and the findings compared with those from a control group. Furthermore, the IgA-antibody is taken into account and presented with examples from the literature. Other possible forms of therapy (combined radio- and polychemotherapy) are also discussed.

Key words

Epstein-Barr virus Nasopharyngeal carcinoma Viral antigens Virology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bayliss GJ, Wolf H (1981) The spontaneous and induced synthesis of Epstein-Barr-virus antigens in RAJI-cells immobilized on surfaces, coated with antilymphocyte globulin. J Gen Virol 54: 397–401Google Scholar
  2. 2.
    Bayliss GJ, Wolf H (1981) An Epstein-Barr-virus protein induces cell-fusion. Proc Natl Acad Sci (USA) 78: 7162–7165Google Scholar
  3. 3.
    Desgranges C, De Thé G (1978) IgA and nasopharyngeal carcinoma. In: De Thé G, Henle W, Rapp F (eds) Oncogenesis and herpes viruses. III. IARC Scientific Publications no. 25, International Agency for Research on Cancer, Lyon, pp 883–891Google Scholar
  4. 4.
    De Thé G, Ho HC, Ablashi DV, Day NE, Macario AJL, Martin Bertheion MC, Pearson G, Sohier R (1975) Nasopharyngeal carcinoma IX. Antibodies to EBNA and correlations with response to other Epstein-Barr-virus antigens in Chinese patients. Int J Cancer 16: 713–721Google Scholar
  5. 5.
    Fischer HA (1979) High Resolution Scintiautoradiography. J Histochem Cytochem 27: 1527–1528Google Scholar
  6. 6.
    Henle W (1971) Antibodies to early antigens induced by Epstein-Barr-virus in infectious mononucleosis. J Infect Dis 124: 58–67Google Scholar
  7. 7.
    Henle G, Henle W (1976) Epstein-Barr-virus specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17: 1–3Google Scholar
  8. 8.
    Henle W, Henle G (1979) Seroepidemiology of the virus. In: Epstein MA, Achong BG (eds) The Epstein-Barr-virus. Springer, Berlin Heidelberg New York, pp 62–78Google Scholar
  9. 9.
    Henle W, Henle G, Ho P, Burtin CH, Cachin Y, Clifford P, de Schryver A, de Thé G, Diel V, Klein G (1970) Antibodies to Epstein-Barr-virus in nasopharyngeal carcinoma, other head and neck neoplasmas and control groups. J Natl Cancer Inst 44: 225–229Google Scholar
  10. 10.
    Henle W, Henle G, Herwitz CA (1974) Epstein-Barr-virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 5: 551–556Google Scholar
  11. 11.
    Henle W, Ho HC, Henle G, Chan JWC, Kwan HC (1977) Nasopharyngeal carcinoma: Significance of changes in Epstein-Barr-virus related antibody patterns following therapy. Int J Cancer 20: 663–672Google Scholar
  12. 12.
    Johnson RB jun, Libby R (1980) Separation of IgM essentially free of IgG from serum for use in systems requiring assay of IgM-type antibodies without interference from rheumatoid factor. J Clin Micro 451–454Google Scholar
  13. 13.
    McLean IW, Nakane PK (1974) Periodate-lysine-paraformaldehyde-fixative. A new fixative for immuno-electron microscopy. J Histochem Cytochem 22: 1077–1083Google Scholar
  14. 14.
    Moar MH, Rosen A, Klein G (1979) Detection of virus- and cellular-determined antigens in situ, using J131-protein A and autoradiography. J Immunol Methods 30: 219–229Google Scholar
  15. 15.
    Purtilo DT, Klein G (1981) Introduction to Epstein-Barr-virus and lymphoproliferative diseases in immunodeficient individuals., Cancer Res 41: 4209–4210Google Scholar
  16. 16.
    Sugden B (1982) Epstein-Barr-virus: a human pathogen inducing lymphoproliferation in vivo and in vitro. Rev Inf Dis 4: 1048–1061Google Scholar
  17. 17.
    Sumaya CV (1975) Seroepidemiological study of Epstein-Barr-virus infections in a rural community. J Infect Dis 131: 403–408Google Scholar
  18. 18.
    Wilmes EH, Wolf H, Deinhardt F, Naumann HH (1979) Die Bedeutung von Epstein-Barr-virus Antikörpern für Diagnose und Verlauf des Nasopharynxcarcinoms. Laryngol Rhinol Otol (Stuttg) 58: 911–913Google Scholar
  19. 19.
    Wilmes E, Wolf H, Deinhardt F, Naumann HH (1981) Epstein-Barr-Virus: ein klinisch relevanter Marker für das Nasenrachencarcinom? Laryngol Rhinol Otol (Stuttg) 60: 4–6Google Scholar
  20. 20.
    Wilmes E, Wolf H (1981) Der Nachweis von Epstein-Barr-Virus Genomen in der Ohrspeicheldrüse. Laryngol Rhinol Otol (Stuttg) 60: 7–10Google Scholar
  21. 21.
    Wilmes E, Wolf H, Deinhardt F, Naumann HH (1981) Epstein-Barr-virus serology in nasopharyngeal carcinomas and related malignancies. In: Grundmann E (ed) Cancer campaign, vol 15. Nasopharyngeal carcinoma. Gustav Fischer Verlag, Stuttgart, pp 145–150Google Scholar
  22. 22.
    Wolf H, Wilmes E, Bayliss GJ (1981) Epstein-Barr-virus: its site of persistence and its role in the development of carcinomas. Haematol Blood Transfus 26: 191–196Google Scholar
  23. 23.
    Wolf H, Bayliss GJ, Wilmes E (1981) Biological properties of Epstein-Barr-virus. In: Grundmann E (ed) Cancer campaign, vol 5. Nasopharyngeal carcinoma. Gustav Fischer Verlag, Stuttgart, pp 101–109Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • N. Falser
    • 1
  1. 1.Universitäts-Hals-Nasen-Ohren-KlinikInnsbruckAustria

Personalised recommendations